View Older Stories

Apr 2, 2026 06:45AM H.C. Wainwright Reiterates Buy Rating on ORIC Pharmaceuticals (ORIC)

Apr 1, 2026 01:22PM Wolfe Research Reiterates Peerperform Rating on ORIC Pharmaceuticals (ORIC)

Apr 1, 2026 06:59AM ORIC Pharmaceuticals (ORIC) Reiterated at Overweight by Cantor Fitzgerald

Mar 12, 2026 11:30PM Upcoming prostate cancer data could drive shares of this pharma company

Mar 11, 2026 10:00AM JPMorgan on ORIC Pharmaceuticals (ORIC): 'We Are Buyers On Weakness'

Mar 9, 2026 02:27PM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC): "today’s move seems like an over-reaction"

Mar 9, 2026 10:06AM Jones Trading on ORIC Pharmaceuticals (ORIC): "We see pressure" following Ipsen's Tazverik withdrawal

Mar 9, 2026 09:32AM Wolfe on ORIC Pharma (ORIC) Amid 12% Decline: 'Net net, we'd frame the newsflow as mixed'

Feb 25, 2026 06:41AM ORIC Pharmaceuticals (ORIC) PT Raised to $25 at H.C. Wainwright

Feb 24, 2026 12:34AM Oppenheimer Reiterates Outperform Rating on ORIC Pharmaceuticals (ORIC)

Feb 23, 2026 05:28PM ORIC Pharmaceuticals, Inc. (ORIC) Tops Q4 EPS by 7c

Jan 15, 2026 06:44AM H.C. Wainwright Reiterates Buy Rating on ORIC Pharmaceuticals (ORIC)

Jan 12, 2026 08:35AM ORIC Pharmaceuticals raises $244 million, extends cash runway to 2028

Jan 7, 2026 03:46AM Piper Sandler Starts ORIC Pharmaceuticals (ORIC) at Overweight

Dec 23, 2025 05:30PM Jefferies lists 5 biotech M&A candidates for 2026

Dec 9, 2025 06:00PM This SMID biotech stock is on JPMorgan's 'Analyst Focus List'

Dec 8, 2025 05:49AM ORIC Pharmaceuticals (ORIC) PT Raised to $25 at Wells Fargo

Dec 5, 2025 06:00AM ORIC Pharmaceuticals reports 35% response rate for lung cancer drug

Dec 4, 2025 06:50AM Goldman Sachs Starts ORIC Pharmaceuticals (ORIC) at Early-Stage Biotech, 'Potential for differentiated approach in prostate cancer'

Nov 20, 2025 01:00AM Evercore ISI Starts ORIC Pharmaceuticals (ORIC) at Outperform

Nov 17, 2025 04:14PM Wolfe Research Starts ORIC Pharmaceuticals (ORIC) at Peerperform

Nov 13, 2025 06:36PM ORIC Pharmaceuticals, Inc. (ORIC) Tops Q3 EPS by 7c

Nov 6, 2025 04:00PM ORIC Pharmaceuticals publishes enozertinib research in Cancer Research

Sep 26, 2025 06:42AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC)

Sep 4, 2025 05:42AM Guggenheim Assumes ORIC Pharmaceuticals (ORIC) at Buy

Aug 18, 2025 04:06PM ORIC Pharmaceuticals names Kevin Brodbeck as chief technical officer

Aug 13, 2025 05:44AM ORIC Pharmaceuticals (ORIC) PT Raised to $23 at Jefferies

Aug 12, 2025 05:55PM ORIC Pharmaceuticals, Inc. (ORIC) Misses Q2 EPS by 3c

Jul 8, 2025 07:33AM Ladenburg Thalmann Starts ORIC Pharmaceuticals (ORIC) at Buy

Jun 3, 2025 07:04AM H.C. Wainwright Reiterates Buy Rating on ORIC Pharmaceuticals (ORIC)

May 29, 2025 06:42AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC)

May 29, 2025 06:20AM Cantor Fitzgerald on ORIC Pharmaceuticals (ORIC): 'Solid Update in Prostate Cancer for ORIC-944'

May 28, 2025 04:09PM ORIC Pharmaceuticals Inc. (ORIC) Announces $125 Million Private Placement at $6.50/sh

May 21, 2025 10:08AM ORIC Pharmaceuticals Inc. (ORIC) Shares Continue Strength Follow Y'Day Sell side Comments, +6pct

May 20, 2025 10:16AM JPMorgan on ORIC Pharamceuticals (ORIC): 'Top Pick', 'ORIC shares should be ~2-4X current levels', PT $20

May 20, 2025 09:59AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC)

May 9, 2025 07:02AM ORIC Pharamceuticals (ORIC) PT Raised to $22 at H.C. Wainwright

May 5, 2025 08:48PM ORIC Pharmaceuticals, Inc. (ORIC) Tops Q1 EPS by 9c

Apr 28, 2025 04:30PM ORIC Pharmaceuticals Inc. (ORIC) Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer

Mar 7, 2025 04:48PM ORIC Pharmaceuticals announces inducement grants to three employees

Feb 18, 2025 07:23AM Stifel Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)

Feb 11, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)

Feb 10, 2025 03:58PM Jones Trading Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)

Feb 10, 2025 11:12AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC) Following Possible ASCO-GU Feb 13 News Title Leak

Feb 10, 2025 11:11AM Cantor Says Buy ORIC Pharmaceuticals Inc. (ORIC) Shares On Possible Mevro Data Leak

Feb 4, 2025 09:38AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC)

Feb 4, 2025 04:58AM Citi Opens 30-Day Upside Catalyst Call on ORIC Pharamceuticals (ORIC)

Jan 13, 2025 08:06AM ORIC Pharmaceuticals Inc. (ORIC) Provides Early Phase 1b Combination Data for ORIC-944

Nov 12, 2024 04:21PM ORIC Pharmaceuticals, Inc. (ORIC) Misses Q3 EPS by 1c

Oct 30, 2024 04:29PM Jones Trading Starts ORIC Pharamceuticals (ORIC) at Buy

View Older Stories